These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 16245354

  • 1. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).
    Belfiglio M, Valentini M, Pellegrini F, De Berardis G, Franciosi M, Rossi MC, Sacco M, Nicolucci A, Interdisciplinary Group for Cancer Care Evaluated (GIVIO) Group.
    Cancer; 2005 Dec 01; 104(11):2334-9. PubMed ID: 16245354
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
    Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA.
    Breast Cancer Res Treat; 2006 Jul 01; 98(2):217-22. PubMed ID: 16538529
    [Abstract] [Full Text] [Related]

  • 4. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M, Graf E, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M, German Adjuvant Breast Cancer Group.
    J Clin Oncol; 2005 Nov 01; 23(31):7842-8. PubMed ID: 16258087
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.
    International Breast Cancer Study GroupWest Swedish Breast Cancer Study Group, Sahlgrenska University Hospital/Mölndal, Göteborgsvägen 31, 431 80 Mölndal, Sweden. c-m.rudenstam@telia.com, Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS.
    J Clin Oncol; 2006 Jan 20; 24(3):337-44. PubMed ID: 16344321
    [Abstract] [Full Text] [Related]

  • 6. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Jan 20; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 7. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.
    J Clin Oncol; 2007 Feb 10; 25(5):486-92. PubMed ID: 17200148
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
    Delozier T, Switsers O, Génot JY, Ollivier JM, Héry M, Namer M, Frenay M, Kerbrat P, Julien JP, Naja A, Janvier M, Macé-Lesec'h J.
    Bull Cancer; 1997 Jan 10; 84(1):25-30. PubMed ID: 9180855
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).
    Alliot C.
    Cancer; 2006 Jul 01; 107(1):215; author reply 215-6. PubMed ID: 16691577
    [No Abstract] [Full Text] [Related]

  • 15. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R, European Organisation for Research and Treatment of Cancer Breast Group, Scottish Breast Cancer Trials Group.
    Eur J Cancer; 2007 Jan 01; 43(2):331-40. PubMed ID: 17134892
    [Abstract] [Full Text] [Related]

  • 16. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    International Breast Cancer Study GroupDivision of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. marco.colleoni@ieo.it, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.
    J Clin Oncol; 2006 Mar 20; 24(9):1332-41. PubMed ID: 16505417
    [Abstract] [Full Text] [Related]

  • 17. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
    Mariotto AB, Feuer EJ, Harlan LC, Abrams J.
    J Natl Cancer Inst Monogr; 2006 Mar 20; (36):7-15. PubMed ID: 17032888
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P, Bonneterre J, Roché H, Lortholary A, Campone M, Van Praagh I, Monnier A, Namer M, Schraub S, Barats JC, Guastalla JP, Goudier MJ, Chapelle-Marcillac I.
    J Clin Oncol; 2004 Dec 01; 22(23):4622-30. PubMed ID: 15505276
    [Abstract] [Full Text] [Related]

  • 20. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
    Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN.
    J Clin Oncol; 2011 Oct 10; 29(29):3869-76. PubMed ID: 21911723
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.